Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

220P - Comparison of efficacy and safety of platinum-based chemotherapy as first-line therapy between B3 thymoma and thymic carcinoma


31 Mar 2023


Poster Display session


Yue Hao


Journal of Hepatology (2023) 18 (4S): S154-S159.


Y. Hao1, J. Si2, J. Jin3, J. Wei4, J. Xiang2, C. Xu5, Z. Song4

Author affiliations

  • 1 Hangzhou/CN
  • 2 Zhejiang Chinese Medical University, hangzhou/CN
  • 3 Zhejiang Cancer Hospital, hangzhou/CN
  • 4 zhejiang cancer hospital, hangzhou/CN
  • 5 Nanjing University School of Medicine, jinling/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 220P


B3 type thymoma is defined as a well-differentiated thymic carcinoma and is similar to a thymic carcinoma. However, the differences between them are not well defined. In addition, the data to compare the efficacy and safety of platinum-based chemotherapy as first-line therapy between B3 thymoma and thymic carcinoma are lacking.


The efficacy and safety of platinum-based chemotherapy as first-line therapy was retrospectively compared between a group of 36 patients with type B3 thymoma and a group of 127 patients with thymic carcinoma treated between January 2009 and March 2022 at the Zhejiang Cancer Hospital. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events were analyzed.


The ORRs for B3 thymoma and thymic carcinoma were 36.1% and 28.3%, respectively (P = 0.370). Among all patients, the difference in PFS between B3 thymoma and thymic carcinoma was not significant (11.3 vs. 10.1 months, P = 0.118). The squamous carcinoma subgroup did not exhibit any differences in PFS compared to B3 thymoma (11.7 vs. 11.3 months, P = 0.161). The result for non-squamous carcinoma subgroup was similar (6.5 vs. 11.3 months, P = 0.128). Furthermore, the OS values for B3 thymoma and thymic carcinoma were not significantly different (58.3 vs. 35.1 months, P = 0.067). However, there were differences in OS between B3 thymoma and non-squamous carcinoma (58.3 vs. 30.6 months, P = 0.031).


B3 thymoma and especially squamous carcinoma patients may be treated using a similar therapy scheme as that utilized for thymic carcinoma.

Legal entity responsible for the study

The authors.


CSCO-Shiyao (Y-SY201901-0068, to Zhengbo Song).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.